tgordi.wordpress.com
May 2016 – Toufigh Gordi, PhD
https://tgordi.wordpress.com/2016/05
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. Expansion of the body weight model. May 30, 2016. May 30, 2016. Toufigh Gordi, PhD. How would a weight loss model look like? May 26, 2016. June 1, 2016. Toufigh Gordi, PhD. As you may guess, activities on the top increase the BW while those in the bottom decrease it. The scenario in front of us is that our subject feels he is overweight and de...
tgordi.wordpress.com
July 2015 – Toufigh Gordi, PhD
https://tgordi.wordpress.com/2015/07
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. Reasons to develop mechanistic PK/PD models. July 31, 2015. Toufigh Gordi, PhD. I will go through an example of a semi-mechanistic PK/PD model in my next blog. For those interested, you may take a look at a model we developed for the antimalarial activity of artemisinin:. Brief introduction to PK/PD models. July 30, 2015. Toufigh Gordi, PhD. PK/PD...
tgordi.wordpress.com
August 2015 – Toufigh Gordi, PhD
https://tgordi.wordpress.com/2015/08
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. August 26, 2015. Toufigh Gordi, PhD. I am quite hopeful that my newly gained knowledge will be a great tool in communicating with others in the added value of a quantitative approach to increase the efficiency of the process. Some misconceptions about half-life. August 14, 2015. Toufigh Gordi, PhD. What does half-life tell us? August 6, 2015.
tgordi.wordpress.com
June 2015 – Toufigh Gordi, PhD
https://tgordi.wordpress.com/2015/06
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. Mathematical models in drug development: An overview. June 26, 2015. Toufigh Gordi, PhD. Pharmacokinetic/pharmacodynamics (PK/PD) models: These models correlate the concentration-time profiles of the drug to the time profile of the observed effect. Having a model for the correlation is very helpful in finding the best dosing regimen that provi...
tgordi.wordpress.com
How would a weight loss model look like? – Toufigh Gordi, PhD
https://tgordi.wordpress.com/2016/05/26/how-would-a-weight-loss-model-look-like
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. How would a weight loss model look like? May 26, 2016. June 1, 2016. Toufigh Gordi, PhD. The (distant) similarities between drug development and weight loss efforts. Expansion of the body weight model. Leave a Reply Cancel reply. Enter your comment here. Fill in your details below or click an icon to log in:. Address never made public). Create a f...
tgordi.wordpress.com
Will larger n help achieve the study endpoint? – Toufigh Gordi, PhD
https://tgordi.wordpress.com/2015/09/10/will-larger-n-help-achieve-the-study-endpoint
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. Will larger n help achieve the study endpoint? September 10, 2015. Toufigh Gordi, PhD. So, what to do when your study results show your drug is better than the competitor/placebo but at a significance level of 0.12 instead of the magical 0.05? How to dose when limited number of subjects are included? Leave a Reply Cancel reply. 10,000 Startup Hours.
tgordi.wordpress.com
Expansion of the body weight model – Toufigh Gordi, PhD
https://tgordi.wordpress.com/2016/05/30/expansion-of-the-body-weight-model
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. Expansion of the body weight model. May 30, 2016. May 30, 2016. Toufigh Gordi, PhD. How would a weight loss model look like? Leave a Reply Cancel reply. Enter your comment here. Fill in your details below or click an icon to log in:. Address never made public). You are commenting using your WordPress.com account. ( Log Out. Follow Blog via Email.
tgordi.wordpress.com
Toufigh Gordi, PhD – Toufigh Gordi, PhD
https://tgordi.wordpress.com/author/tgordi
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. Author: Toufigh Gordi, PhD. Expansion of the body weight model. May 30, 2016. May 30, 2016. Toufigh Gordi, PhD. How would a weight loss model look like? May 26, 2016. June 1, 2016. Toufigh Gordi, PhD. As you may guess, activities on the top increase the BW while those in the bottom decrease it. The scenario in front of us is that our subject f...
tgordi.wordpress.com
Toufigh Gordi, PhD – Page 2 – PK/PD modeling & simulation in drug development
https://tgordi.wordpress.com/page/2
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. Some misconceptions about half-life. August 14, 2015. Toufigh Gordi, PhD. What does half-life tell us? What other use does half-life estimate have? A semi-mechanistic PK/PD model. August 6, 2015. Toufigh Gordi, PhD. Compartment. And that’s pretty much it! In general, I have found that the more mechanistic a model is, the easier it becomes to get i...
tgordi.wordpress.com
September 2015 – Toufigh Gordi, PhD
https://tgordi.wordpress.com/2015/09
Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Simulation in Drug Development. Toufigh Gordi, PhD. PK/PD modeling and simulation in drug development. How to dose when limited number of subjects are included? September 28, 2015. Toufigh Gordi, PhD. One could of course ask, if we know that the results we are getting from a certain study design are not really representative and do not add much to our knowledge about a drug in certain (animal) population, why do we continue with the same design?